| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Grace Therapeutics, Inc. | Chief Executive Officer, Director | Stock Option (Right to Buy) | 225,400 | 14 Apr 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| GRCE | Grace Therapeutics, Inc. | 14 Apr 2025 | 1 | $0 | 4 | Chief Executive Officer, Director | 16 Apr 2025, 20:58 |
| GRCE | Acasti Pharma Inc. | 06 May 2024 | 1 | $0 | 4 | Chief Executive Officer, Director | 08 May 2024, 19:18 |
| GRCE | Acasti Pharma Inc. | 19 Dec 2023 | 1 | $0 | 4 | Chief Executive Officer, Director | 20 Dec 2023, 16:05 |
| GRCE | Acasti Pharma Inc. | 14 Jul 2023 | 1 | $0 | 4 | Chief Executive Officer | 18 Jul 2023, 16:26 |
| GRCE | Acasti Pharma Inc. | 09 Sep 2022 | 0 | $0 | 3 | CCO | 16 Sep 2022, 16:18 |